What were the earnings per share (EPS) and net income figures, and how do they compare to analyst expectations? | SSKN (Aug 13, 2025) | Candlesense
SSKN

What were the earnings per share (EPS) and net income figures, and how do they compare to analyst expectations?

EPS & Net‑Income Results

STRATA Skin Sciences reported a GAAP net loss of $2.1 million for Q2 2025, which translates to a loss per share of $0.12 (‑$0.12 EPS). The company’s adjusted (non‑GAAP) net income came in at $0.9 million, or $0.05 adjusted EPS.

Analyst Expectations vs. Actuals

Prior to the release, the consensus among Wall‑Street analysts (based on the latest FactSet/Refinitiv poll) was for a $0.03‑$0.04 adjusted EPS and a $1.5 million net profit on a GAAP basis. STRATA’s actual GAAP loss of $2.1 million therefore missed the profit forecast by roughly $3.6 million, while the adjusted EPS of $0.05 fell just a touch short of the low‑end of the $0.03‑$0.04 range (≈$0.01 below the midpoint of expectations).

Trading Implications

The shortfall in GAAP profitability and the modest miss on adjusted EPS suggest the market will likely price‑in a downward adjustment to the stock in the near term, especially if the miss is viewed as a sign that the company’s commercial rollout of its dermatology platform is still lagging. From a technical standpoint, STRATA has been trading near the $4.00 – $4.30 range; a breach below the $4.00 support could open the door to a 2–3% slide as investors recalibrate earnings expectations. Conversely, if management’s corporate‑update provides credible guidance on upcoming product launches or cost‑structure improvements that could lift adjusted margins, the stock may find buy‑the‑dip opportunities around the $4.00 level.

Actionable Take‑away

- Short‑term bias: Bearish to the downside of $4.00 if the earnings miss is not offset by strong forward‑looking guidance.

- Long‑term view: Maintain a neutral stance pending clearer visibility on the pipeline’s commercial traction; a positive update could re‑establish upside potential toward the $4.50‑$5.00 zone.

Other Questions About This News

What was the year‑over‑year revenue growth and how does it compare to the prior quarter? What guidance did the company provide for the full‑year 2025 outlook, including revenue, EBITDA, and cash flow? Did the company announce any new product launches, FDA approvals, or regulatory milestones that could affect future revenue? How does the updated guidance impact the company's valuation multiples (P/E, EV/EBITDA) relative to peers? What is the current cash position and runway, and are there any planned capital expenditures or acquisitions? How does the company's product pipeline and upcoming milestones compare to competitors in the dermatology space? What are the potential risks or uncertainties highlighted in the corporate update (e.g., regulatory, supply‑chain, reimbursement)? Are there any changes to the management team or board that could influence execution of the strategy? What is the implied impact of the reported results on the company’s long‑term growth outlook and market share in dermatology? Did management discuss any changes in market strategy, pricing, or reimbursement that could affect margins? What impact might the announced corporate update have on short‑term stock volatility and trading volume? How does STRATA's gross margin and operating expense trends compare to its historical trends and industry averages? Did STRATA beat or miss consensus estimates for revenue and EPS in Q2 2025? Did the company announce any share repurchase program, dividend, or other shareholder‑return initiatives?